Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Campath versus Rebif in early active relapsing-remitting multiple sclerosis
ISRCTN87885087Phase 2Completed
- Sponsor
- ILEX Oncology, Inc.
- Start
- Dec 2002
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of alemtuzumab and interferon beta-1a in multiple sclerosis (MS) (3 arms), sponsored by ILEX Oncology, Inc. Primary endpoints: Time to sustained accumulation of disability and Relapse rate. Started Dec 2002; status: completed.
02
Drugs
alemtuzumabinterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN87885087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN87885087.